30134-08-8

Usage

Uses

Used in Pharmaceutical Industry:
[(3-phenylpropyl)sulfanyl]acetic acid is used as a building block for the production of various pharmaceuticals. Its unique structure and chemical properties allow it to be a key component in the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, [(3-phenylpropyl)sulfanyl]acetic acid is employed as a precursor in the synthesis of different agrochemicals. Its versatile nature enables the creation of compounds that can be used in the development of pesticides, herbicides, and other agricultural products.
Used in Organic Synthesis:
[(3-phenylpropyl)sulfanyl]acetic acid is used as a precursor in the synthesis of other organic compounds. Its distinctive structure and reactivity make it a valuable starting material for the creation of a wide range of organic molecules, contributing to the advancement of organic chemistry and its applications.

Upstream product

• 24734-68-7 3-Phenylpropane-1-thiol 
• 637-59-2 1-Bromo-3-phenylpropane 
• 68-11-1 mercaptoacetic acid 
• 79-11-8 chloroacetic acid 

Downstream Products

• 1609007-93-3 E-acetic acid 2-acetoxy-4-[2-(3-phenylpropane-1-sulfonyl)vinyl]phenyl ester 
• 1609008-01-6 E-acetic acid 2-acetoxy-4-[2-(3-phenylpropane-1-sulfinyl)vinyl]phenyl ester 
• 174455-75-5 7-chloro-5-nitro-4-hydroxy-3-(3-phenylpropylthio)-2(1H)-quinolone 
• 100126-69-0 (3-phenyl-propylsulfanyl)-acetyl chloride 
• 30134-09-9 methyl 2-[(3-phenylpropyl)thio]acetate 

Relevant academic research and scientific papers

ω-Quinazolinonylalkyl aryl ureas as reversible inhibitors of monoacylglycerol lipase

The serine hydrolase monoacylglycerol lipase (MAGL) is involved in a plethora of pathological conditions, in particular pain and inflammation, various types of cancer, metabolic, neurological and cardiovascular disorders, and is therefore a promising target for drug development. Although a large number of irreversible-acting MAGL inhibitors have been discovered over the past years, there are only few compounds known so far which inhibit the enzyme in a reversible manner. Therefore, much effort is put into the development of novel chemical entities showing reversible inhibitory behavior, which is thought to cause less undesired side effects. To explore a wide range of chemical structures as MAGL binders, we have applied a virtual screening approach by docking small molecules into the crystal structure of human MAGL (hMAGL) and envisaged a library of 45 selected compounds which were then synthesized. Biochemical investigations included the determination of the inhibitory potency on hMAGL and two related hydrolases, i.e. human fatty acid amide hydrolase (hFAAH) and murine cholesterol esterase (mCEase). The most promising candidates from theses analyses, i.e. three ω-quinazolinonylalkyl aryl ureas bearing alkyl spacers of three to five methylene groups, exhibited IC50 values of 20–41 μM and reversible, detergent-insensitive behavior towards hMAGL. Among these compounds, the inhibitor 1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-(4-oxo-3,4-dihydroquinazolin-2-yl)butyl)urea (96) was selected for further kinetic characterization, yielding a dissociation constant Ki = 15.4 μM and a mixed-type inhibition with a pronounced competitive component (α = 8.94). This mode of inhibition was further supported by a docking experiment, which suggested that the inhibitor occupies the substrate binding pocket of hMAGL.

Styryl sulfones compound, its preparation method and its use as neuroprotective agents

The application relates to design of a novel molecule with ester group substituted by sulfone group by using a caffeic acid phenethyl ester (CAPE) with neuroprotective activity extracted from natural propolis as a primer according to bioisosterism principle and hydrogen-bond interaction theory; and the molecule has a structural general formula I, and the definition of each group is shown in the claims. The invention also relates to compound in vitroantioxidation capability evaluation, neuroprotective activity evaluation on cell level and traverse blood brain barrier ability evaluation. Activity evaluation results show that the synthesized novel compound has enhanced neuroprotective activity and can easily traverse the blood brain barrier, thus becoming a novel neuroprotective agent for treating neurodegenerative diseases.

E-3,4-di-calcium method for preparing vinyl sulfoxide compound thereof as a neuroprotective pharmaceutical application

The invention relates to an application of E-3,4-dihydroxyphenylvinyl sulfoxide represented by the formula I in preparation of nerve protection drugs for treating neurodegenerative diseases, wherein the definitions of each group in the formula I are listed in the description. The invention also relates to a preparation method of E-3,4-dihydroxyphenylvinyl sulfoxide.

Design, synthesis, and biological evaluation of (E)-3,4-dihydroxystyryl aralkyl sulfones and sulfoxides as novel multifunctional neuroprotective agents

Novel (E)-3,4-dihydroxystyryl aralkyl sulfones and sulfoxides were designed and synthesized as new analogues of 1, which showed interesting multifunctional neuroprotective effects, including antioxidative and antineuroinflammatory properties. Specifically, target compounds display excellent potency in scavenging reactive free radicals and demonstrate potent effects against various kinds of toxicities, including H2O2, 6-hydroxydopamine, and lipopolysaccharide in different types of neuronal cells. The antioxidative properties of the target compounds are more potent than that of 1, and the antineuroinflammatory properties are less strong than that of 1. According to the parallel artificial membrane permeation assay for the blood-brain barrier, target compounds possess greater blood-brain barrier (BBB) permeability than 1. In short, due to improvement of the antioxidative effect, stability, and BBB permeability, (E)-3,4-dihydroxystyryl aralkyl sulfones and sulfoxides can thus be considered as potential multifunctional neuroprotective agents and serve as new lead candidates in the treatment of neurodegenerative diseases.

Macrolides with antibacterial activity

The invention provides new macrolides antibiotics of formula (I) with improved biological properties and improved stability formula (I): wherein R1 is hydrogen, cyano, —S(L)mR2, —S(O)(L)mR2, or —S(O)